Free 7-day Trial
All Articles and Columns »

XenoPort Inc. Reports Operating Results (10-Q)

August 08, 2012 | About:

10qk

18 followers
XenoPort Inc. (XNPT) filed Quarterly Report for the period ended 2012-06-30.

Xenoport, Inc. has a market cap of $273.3 million; its shares were traded at around $8.64 with and P/S ratio of 6.3.
This is the annual revenues and earnings per share of XNPT over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of XNPT.


Highlight of Business Operations:

GSK recorded $1.6 million and $2.9 million of net sales of Horizant for the three and six months ended June 30, 2012, respectively. Under our collaboration agreement with GSK, all allowable expenses and sales of Horizant are accounted for using a joint profit and loss, or P&L, statement, in which we and GSK share in the resulting operating pre-tax profits and losses. Our share of losses from the joint P&L will be forgiven up to a maximum of $10.0 million, of which approximately $8.3 million had been forgiven through June 30, 2012. The payment of our share of additional losses, if any, would be deferred and payable without interest over a four-year period of time following the first quarter in which the joint P&L is profitable. GSK is responsible for the development, including post-marketing commitments, of Horizant for RLS and PHN in the United States.

Our collaboration revenue consisted of the recognition of revenues from up-front and milestone payments from our collaboration with Astellas. Our net revenue from unconsolidated joint operating activities consisted of the recognition of revenues from up-front, milestone and contingent event-based payments and the recognition of our share of operating losses resulting from our election to co-promote Horizant in the United States with GSK. In connection with the amendment and restatement of our collaboration agreement with GSK in November 2010, our share of operating losses is forgiven up to a maximum of $10.0 million, of which approximately $8.3 million had been forgiven through June 30, 2012. Pursuant to the agreement, GSK is responsible for recording sales of Horizant in the United States. For the three and six months ended June 30, 2012, net sales in the United States of Horizant as recorded by GSK were $1.6 million and $2.9 million, respectively.

The decrease in net revenue from unconsolidated joint operating activities for the three and six months ended June 30, 2012 compared to the same periods in 2011 was due to the recognition of a $30.0 million contingent payment from GSK in connection with the first shipment of Horizant to a wholesaler in 2011, offset by the recognition of a $10.0 million contingent payment from GSK in connection with the first commercial sale of Horizant for the management of PHN in adults in 2012.

The decrease in collaboration revenue for the three months ended June 30, 2012 compared to the same period in 2011 was due to the recognition of a $7.0 million milestone payment from Astellas in connection with the Horizant FDA approval in 2011.

The increase in collaboration revenue for the six months ended June 30, 2012 compared to the same period in 2011 was due to the recognition of a $10.0 million milestone payment from Astellas in connection with the approval of Regnite in Japan in 2012, offset by the recognition of a $7.0 million milestone payment from Astellas in connection with the Horizant FDA approval in 2011.

Read the The complete Report

About the author:

10qk
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide